December 7, 2023
Could a simple blood test detect Alzheimer’s disease years before symptoms appear? New research from Resonant—a Utah-based biotech company that develops diagnostic tests for neurodegenerative diseases—suggests it may be possible, reports the New York Post.
Researchers said its new test achieved 100% accuracy in identifying patients with Alzheimer’s disease and individuals with mild cognitive impairment (MCI) who went on to develop Alzheimer’s disease within five years.
In the study, a total of 50 blood plasma samples were tested. These included 25 older control individuals, 13 patients who had been diagnosed with Alzheimer’s, six patients with mild cognitive impairment who later developed Alzheimer’s, and six mild cognitive impairment patients who did not develop Alzheimer’s.
The findings were published in Frontiers in Neurology on October 31.
The blood test works by detecting the presence of DNA released from the brain’s neurons—or nerve cells when they die—according to lead researcher Chad Pollard, a doctorate student and research assistant at Brigham Young University.
“All cells, to some degree, release fragments of DNA called cell-free DNA (cfDNA) into their environment,” Pollard, who is also a co-founder of Resonant, told Fox News Digital in an email.
“Under normal, healthy conditions, cfDNA from neurons is undetectable in blood circulation, but during neurodegeneration, the amount of cfDNA that is released from these cells significantly increases and can be detected in the blood.”
Beyond Alzheimer’s disease, the researchers are also actively working to apply this technology to other neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS, also called Lou Gehrig’s disease), noted Pollard.
View the company’s peer-reviewed research or join the waitlist for the test at its website, http://www.resonantdx.com.
Research contact: @nypost